サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1530950

腎臓がん診断薬市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測

Kidney Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 189 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
腎臓がん診断薬市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測
出版日: 2024年06月25日
発行: Transparency Market Research
ページ情報: 英文 189 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

腎臓がん診断薬市場- 調査範囲

TMRの調査レポート「腎臓がん診断薬の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の腎臓がん診断薬市場の収益と予測を提供しています。また、2024年から2034年までの世界の腎臓がん診断薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、腎臓がん診断薬市場を推察しました。

市場スナップショット
2023年の市場規模 36億米ドル
2034年の市場規模 69億米ドル
CAGR 6.2%

当レポートでは、世界の腎臓がん診断薬市場の競合情勢について調査しています。世界の腎臓がん診断薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の腎臓がん診断薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020年～2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：製品タイプ別、2020年～2034年
    • プラットフォームベースの製品
    • 計測機器ベースの製品
    • キットと試薬
    • その他（消耗品等）
  • 市場の魅力：製品タイプ別

第7章 世界の市場分析と予測：検査タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：検査タイプ別、2020年～2034年
    • 生検
    • 画像検査
    • 血液検査
    • その他（遺伝子検査等）
  • 市場の魅力：検査タイプ別

第8章 世界の市場分析と予測：がんのステージ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：がんのステージ別、2020年～2034年
    • ステージ1
    • ステージ2
    • ステージ3
    • ステージ4
  • 市場の魅力：がんステージ別

第9章 世界の市場分析と予測：腫瘍タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：腫瘍タイプ別、2020年～2034年
    • 腎細胞がん
    • 明細胞がん
    • 非明細胞がん
  • 市場の魅力：腫瘍タイプ別

第10章 世界の市場分析と予測：技術別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：技術別、2020年～2034年
    • 蛍光in situハイブリダイゼーション
    • 次世代シーケンシング
    • 蛍光免疫測定法
    • 比較ゲノムハイブリダイゼーション
    • その他（免疫組織化学など）
  • 市場の魅力：技術別

第11章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 病院
    • がん研究センター
    • 腫瘍科クリニック
    • 診断センター
    • 外来手術センター
    • その他（調査機関等）
  • 市場の魅力：エンドユーザー別

第12章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第13章 北米の市場分析と予測

第14章 欧州の市場分析と予測

第15章 アジア太平洋地域の市場分析と予測

第16章 ラテンアメリカの市場分析と予測

第17章 中東・アフリカの市場分析と予測

第18章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023）
  • 企業プロファイル
    • Siemens Healthineers
    • Koninklijke Philips N.V.
    • FUJIFILM Holdings Corporation
    • Grail
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific
    • Myriad Genetics, Inc.
    • Canon Medical Systems Corporation
    • QIAGEN N.V.
    • Illumina, Inc.
    • Ambry Genetics
    • Invitae Corp.
    • Centogene N.V.
図表

List of Tables

  • Table 01: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 02: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 03: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 04: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 05: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Technology, 2020-2034
  • Table 06: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 07: Global Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 08: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 09: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 10: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 11: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 12: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 13: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
  • Table 14: North America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 15: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 16: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 17: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 18: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 19: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 20: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
  • Table 21: Europe Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 22: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 23: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 24: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 25: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 26: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 27: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
  • Table 28: Asia Pacific Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 29: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 30: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 31: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 32: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 33: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 34: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
  • Table 35: Latin America Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 36: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 37: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 38: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Test Type, 2020-2034
  • Table 39: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, By Cancer Stage, 2020-2034
  • Table 40: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Tumor Type, 2020-2034
  • Table 41: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by Technology, 2020-2034
  • Table 42: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Kidney Cancer Diagnostics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Product Type, 2023
  • Figure 03: Global Kidney Cancer Diagnostics Market Value Share, by Product Type, 2023
  • Figure 04: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Test Type, 2023
  • Figure 05: Global Kidney Cancer Diagnostics Market Value Share, by Test Type, 2023
  • Figure 06: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), By Cancer Stage, 2023
  • Figure 07: Global Kidney Cancer Diagnostics Market Value Share, By Cancer Stage, 2023
  • Figure 08: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Tumor Type, 2023
  • Figure 09: Global Kidney Cancer Diagnostics Market Value Share, by Tumor Type, 2023
  • Figure 10: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Technology, 2023
  • Figure 11: Global Kidney Cancer Diagnostics Market Value Share, by Technology, 2023
  • Figure 12: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by End-user, 2023
  • Figure 13: Global Kidney Cancer Diagnostics Market Value Share, by End-user, 2023
  • Figure 14: Global Kidney Cancer Diagnostics Market Value Share, by Region, 2023
  • Figure 15: Global Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 16: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 17: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 18: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 19: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 20: Global Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 21: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
  • Figure 22: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Tumor Type, 2023
  • Figure 23: Global Kidney Cancer Diagnostics Market Value Share, by Tumor Type, 2023
  • Figure 24: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by Technology, 2023
  • Figure 25: Global Kidney Cancer Diagnostics Market Value Share, by Technology, 2023
  • Figure 26: Global Kidney Cancer Diagnostics Market Revenue (US$ Bn), by End-user, 2023
  • Figure 27: Global Kidney Cancer Diagnostics Market Value Share, by End-user, 2023
  • Figure 28: Global Kidney Cancer Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 29: Global Kidney Cancer Diagnostics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 30: North America Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 31: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 32: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 33: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 34: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 35: North America Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 36: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
  • Figure 37: North America Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 38: North America Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 39: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 40: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 41: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
  • Figure 42: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
  • Figure 43: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 44: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Europe Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 49: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 50: Europe Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 51: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
  • Figure 52: North America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 53: Europe Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 54: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 55: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 56: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
  • Figure 57: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
  • Figure 58: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 59: Europe Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 60: Asia Pacific Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 61: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 62: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 63: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 64: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 65: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 66: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
  • Figure 67: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 68: Asia Pacific Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 69: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 70: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 71: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2024-2034
  • Figure 72: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
  • Figure 73: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 74: Asia Pacific Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 75: Latin America Kidney Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 76: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 77: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 78: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 79: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 80: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 81: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
  • Figure 82: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 83: Latin America Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 84: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 85: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 86: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
  • Figure 87: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
  • Figure 88: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 89: Latin America Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 90: Middle East & Africa Kidney Cancer Diagnostics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 91: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 92: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 93: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 94: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Test Type, 2023 and 2034
  • Figure 95: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, By Cancer Stage, 2023 and 2034
  • Figure 96: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Tumor Type, 2023 and 2034
  • Figure 97: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 98: Middle East & Africa Kidney Cancer Diagnostics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 99: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 100: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2024-2034
  • Figure 101: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, By Cancer Stage, 2023-2034
  • Figure 102: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Tumor Type, 2024-2034
  • Figure 103: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 104: Middle East & Africa Kidney Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL78590

Kidney Cancer Diagnostics Market - Scope of Report

TMR's report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.

Market Snapshot
Market Value in 2023US$ 3.6 Bn
Market Value in 2034US$ 6.9 Bn
CAGR6.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.

The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.

Key Questions Answered in Global kidney cancer diagnostics Market Report:

  • What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
  • What are the opportunities in the global kidney cancer diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Kidney Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Kidney Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2020-2034
    • 6.3.1. Platform-based Products
    • 6.3.2. Instrument-based Products
    • 6.3.3. Kits and Reagents
    • 6.3.4. Others (Consumables, etc.)
  • 6.4. Market Attractiveness, by Product Type

7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Test Type, 2020-2034
    • 7.3.1. Biopsy
    • 7.3.2. Imaging Tests
    • 7.3.3. Blood Tests
    • 7.3.4. Others (Genetic Testing, etc.)
  • 7.4. Market Attractiveness, by Test Type

8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Cancer Stage, 2020-2034
    • 8.3.1. Stage 1
    • 8.3.2. Stage 2
    • 8.3.3. Stage 3
    • 8.3.4. Stage 4
  • 8.4. Market Attractiveness, By Cancer Stage

9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Tumor Type, 2020-2034
    • 9.3.1. Renal Cell Carcinoma
    • 9.3.2. Clear Cell Carcinoma
    • 9.3.3. Non-clear Cell Carcinoma
  • 9.4. Market Attractiveness, by Tumor Type

10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology

  • 10.1. Introduction and Definitions
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Tumor Type, 2020-2034
    • 10.3.1. Fluorescent In Situ Hybridization
    • 10.3.2. Next Generation Sequencing
    • 10.3.3. Fluoroimmunoassay
    • 10.3.4. Comparative Genomic Hybridization
    • 10.3.5. Others (Immunohistochemical, etc.)
  • 10.4. Market Attractiveness, by Tumor Type

11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user

  • 11.1. Introduction and Definitions
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by End-user, 2020-2034
    • 11.3.1. Hospitals
    • 11.3.2. Cancer Research Centers
    • 11.3.3. Oncology Clinics
    • 11.3.4. Diagnostic Centers
    • 11.3.5. Ambulatory Surgery Centers
    • 11.3.6. Others (Research Institutes, etc.)
  • 11.4. Market Attractiveness, by End-user

12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2020-2034
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness, by Region

13. North America Kidney Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2020-2034
    • 13.2.1. Platform-based Products
    • 13.2.2. Instrument-based Products
    • 13.2.3. Kits and Reagents
    • 13.2.4. Others (Consumables, etc.)
  • 13.3. Market Attractiveness, by Product Type
  • 13.4. Market Value Forecast, by Test Type, 2020-2034
    • 13.4.1. Biopsy
    • 13.4.2. Imaging Tests
    • 13.4.3. Blood Tests
    • 13.4.4. Others (Genetic Testing, etc.)
  • 13.5. Market Attractiveness, by Test Type
  • 13.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 13.6.1. Stage 1
    • 13.6.2. Stage 2
    • 13.6.3. Stage 3
    • 13.6.4. Stage 4
  • 13.7. Market Attractiveness, By Cancer Stage
  • 13.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 13.8.1. Renal Cell Carcinoma
    • 13.8.2. Clear Cell Carcinoma
    • 13.8.3. Non-clear Cell Carcinoma
  • 13.9. Market Attractiveness, by Tumor Type
  • 13.10. Market Value Forecast, by Technology 2020-2034
    • 13.10.1. Fluorescent In Situ Hybridization
    • 13.10.2. Next Generation Sequencing
    • 13.10.3. Fluoroimmunoassay
    • 13.10.4. Comparative Genomic Hybridization
    • 13.10.5. Others (Immunohistochemical, etc.)
  • 13.11. Market Attractiveness, by Technology
  • 13.12. Market Value Forecast, by End-user, 2020-2034
    • 13.12.1. Hospitals
    • 13.12.2. Cancer Research Centers
    • 13.12.3. Oncology Clinics
    • 13.12.4. Diagnostic Centers
    • 13.12.5. Ambulatory Surgery Centers
    • 13.12.6. Others (Research Institutes, etc.)
  • 13.13. Market Attractiveness, by End-user
  • 13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.14.1. U.S.
    • 13.14.2. Canada
  • 13.15. Market Attractiveness Analysis
    • 13.15.1. By Product Type
    • 13.15.2. By Test Type
    • 13.15.3. By Cancer Stage
    • 13.15.4. By Tumor Type
    • 13.15.5. By End-user
    • 13.15.6. By Country

14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product Type, 2020-2034
    • 14.2.1. Platform-based Products
    • 14.2.2. Instrument-based Products
    • 14.2.3. Kits and Reagents
    • 14.2.4. Others (Consumables, etc.)
  • 14.3. Market Attractiveness, by Product Type
  • 14.4. Market Value Forecast, by Test Type, 2020-2034
    • 14.4.1. Biopsy
    • 14.4.2. Imaging Tests
    • 14.4.3. Blood Tests
    • 14.4.4. Others (Genetic Testing, etc.)
  • 14.5. Market Attractiveness, by Test Type
  • 14.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 14.6.1. Stage 1
    • 14.6.2. Stage 2
    • 14.6.3. Stage 3
    • 14.6.4. Stage 4
  • 14.7. Market Attractiveness, By Cancer Stage
  • 14.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 14.8.1. Renal Cell Carcinoma
    • 14.8.2. Clear Cell Carcinoma
    • 14.8.3. Non-clear Cell Carcinoma
  • 14.9. Market Attractiveness, by Tumor Type
  • 14.10. Market Value Forecast, by Technology, 2020-2034
    • 14.10.1. Fluorescent In Situ Hybridization
    • 14.10.2. Next Generation Sequencing
    • 14.10.3. Fluoroimmunoassay
    • 14.10.4. Comparative Genomic Hybridization
    • 14.10.5. Others (Immunohistochemical, etc.)
  • 14.11. Market Attractiveness, by Technology
  • 14.12. Market Value Forecast, by End-user, 2020-2034
    • 14.12.1. Hospitals
    • 14.12.2. Cancer Research Centers
    • 14.12.3. Oncology Clinics
    • 14.12.4. Diagnostic Centers
    • 14.12.5. Ambulatory Surgery Centers
    • 14.12.6. Others (Research Institutes, etc.)
  • 14.13. Market Attractiveness, by End-user
  • 14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.14.1. Germany
    • 14.14.2. U.K.
    • 14.14.3. France
    • 14.14.4. Italy
    • 14.14.5. Spain
    • 14.14.6. Rest of Europe
  • 14.15. Market Attractiveness Analysis
    • 14.15.1. By Product Type
    • 14.15.2. By Test Type
    • 14.15.3. By Cancer Stage
    • 14.15.4. By Tumor Type
    • 14.15.5. By End-user
    • 14.15.6. By Country/Sub-region

15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Product Type, 2020-2034
    • 15.2.1. Platform-based Products
    • 15.2.2. Instrument-based Products
    • 15.2.3. Kits and Reagents
    • 15.2.4. Others (Consumables, etc.)
  • 15.3. Market Attractiveness, by Product Type
  • 15.4. Market Value Forecast, by Test Type, 2020-2034
    • 15.4.1. Biopsy
    • 15.4.2. Imaging Tests
    • 15.4.3. Blood Tests
    • 15.4.4. Others (Genetic Testing, etc.)
  • 15.5. Market Attractiveness, by Test Type
  • 15.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 15.6.1. Stage 1
    • 15.6.2. Stage 2
    • 15.6.3. Stage 3
    • 15.6.4. Stage 4
  • 15.7. Market Attractiveness, By Cancer Stage
  • 15.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 15.8.1. Renal Cell Carcinoma
    • 15.8.2. Clear Cell Carcinoma
    • 15.8.3. Non-clear Cell Carcinoma
  • 15.9. Market Attractiveness, by Tumor Type
  • 15.10. Market Value Forecast, by Technology 2020-2034
    • 15.10.1. Fluorescent In Situ Hybridization
    • 15.10.2. Next Generation Sequencing
    • 15.10.3. Fluoroimmunoassay
    • 15.10.4. Comparative Genomic Hybridization
    • 15.10.5. Others (Immunohistochemical, etc.)
  • 15.11. Market Attractiveness, by Technology
  • 15.12. Market Value Forecast, by End-user, 2020-2034
    • 15.12.1. Hospitals
    • 15.12.2. Cancer Research Centers
    • 15.12.3. Oncology Clinics
    • 15.12.4. Diagnostic Centers
    • 15.12.5. Ambulatory Surgery Centers
    • 15.12.6. Others (Research Institutes, etc.)
  • 15.13. Market Attractiveness, by End-user
  • 15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.14.1. China
    • 15.14.2. Japan
    • 15.14.3. India
    • 15.14.4. Australia & New Zealand
    • 15.14.5. Rest of Asia Pacific
  • 15.15. Market Attractiveness Analysis
    • 15.15.1. By Product Type
    • 15.15.2. By Test Type
    • 15.15.3. By Cancer Stage
    • 15.15.4. By Tumor Type
    • 15.15.5. By End-user
    • 15.15.6. By Country/Sub-region

16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Product Type, 2020-2034
    • 16.2.1. Platform-based Products
    • 16.2.2. Instrument-based Products
    • 16.2.3. Kits and Reagents
    • 16.2.4. Others (Consumables, etc.)
  • 16.3. Market Attractiveness, by Product Type
  • 16.4. Market Value Forecast, by Test Type, 2020-2034
    • 16.4.1. Biopsy
    • 16.4.2. Imaging Tests
    • 16.4.3. Blood Tests
    • 16.4.4. Others (Genetic Testing, etc.)
  • 16.5. Market Attractiveness, by Test Type
  • 16.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 16.6.1. Stage 1
    • 16.6.2. Stage 2
    • 16.6.3. Stage 3
    • 16.6.4. Stage 4
  • 16.7. Market Attractiveness, By Cancer Stage
  • 16.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 16.8.1. Renal Cell Carcinoma
    • 16.8.2. Clear Cell Carcinoma
    • 16.8.3. Non-clear Cell Carcinoma
  • 16.9. Market Attractiveness, by Tumor Type
  • 16.10. Market Value Forecast, by Technology, 2020-2034
    • 16.10.1. Fluorescent In Situ Hybridization
    • 16.10.2. Next Generation Sequencing
    • 16.10.3. Fluoroimmunoassay
    • 16.10.4. Comparative Genomic Hybridization
    • 16.10.5. Others (Immunohistochemical, etc.)
  • 16.11. Market Attractiveness, by Technology
  • 16.12. Market Value Forecast, by End-user, 2020-2034
    • 16.12.1. Hospitals
    • 16.12.2. Cancer Research Centers
    • 16.12.3. Oncology Clinics
    • 16.12.4. Diagnostic Centers
    • 16.12.5. Ambulatory Surgery Centers
    • 16.12.6. Others (Research Institutes, etc.)
  • 16.13. Market Attractiveness, by End-user
  • 16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 16.14.1. Brazil
    • 16.14.2. Mexico
    • 16.14.3. Rest of Latin America
  • 16.15. Market Attractiveness Analysis
    • 16.15.1. By Product Type
    • 16.15.2. By Test Type
    • 16.15.3. By Cancer Stage
    • 16.15.4. By Tumor Type
    • 16.15.5. By End-user
    • 16.15.6. By Country/Sub-region

17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Product Type, 2020-2034
    • 17.2.1. Platform-based Products
    • 17.2.2. Instrument-based Products
    • 17.2.3. Kits and Reagents
    • 17.2.4. Others (Consumables, etc.)
  • 17.3. Market Attractiveness, by Product Type
  • 17.4. Market Value Forecast, by Test Type, 2020-2034
    • 17.4.1. Biopsy
    • 17.4.2. Imaging Tests
    • 17.4.3. Blood Tests
    • 17.4.4. Others (Genetic Testing, etc.)
  • 17.5. Market Attractiveness, by Test Type
  • 17.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 17.6.1. Stage 1
    • 17.6.2. Stage 2
    • 17.6.3. Stage 3
    • 17.6.4. Stage 4
  • 17.7. Market Attractiveness, By Cancer Stage
  • 17.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 17.8.1. Renal Cell Carcinoma
    • 17.8.2. Clear Cell Carcinoma
    • 17.8.3. Non-clear Cell Carcinoma
  • 17.9. Market Attractiveness, by Tumor Type
  • 17.10. Market Value Forecast, by Technology, 2020-2034
    • 17.10.1. Fluorescent In Situ Hybridization
    • 17.10.2. Next Generation Sequencing
    • 17.10.3. Fluoroimmunoassay
    • 17.10.4. Comparative Genomic Hybridization
    • 17.10.5. Others (Immunohistochemical, etc.)
  • 17.11. Market Attractiveness, by Technology
  • 17.12. Market Value Forecast, by End-user, 2020-2034
    • 17.12.1. Hospitals
    • 17.12.2. Ambulatory Surgical Centers
    • 17.12.3. Nursing Centers
    • 17.12.4. Others (Long Term Care Centers, etc.)
  • 17.13. Market Attractiveness, by End-user
  • 17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 17.14.1. GCC Countries
    • 17.14.2. South Africa
    • 17.14.3. Rest of Middle East & Africa
  • 17.15. Market Attractiveness Analysis
    • 17.15.1. By Product Type
    • 17.15.2. By Test Type
    • 17.15.3. By Cancer Stage
    • 17.15.4. By Tumor Type
    • 17.15.5. By End-user
    • 17.15.6. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 18.2. Market Share Analysis, by Company (2023)
  • 18.3. Company Profiles
    • 18.3.1. Siemens Healthineers
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Financial Overview
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Strategic Overview
    • 18.3.2. Koninklijke Philips N.V.
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Financial Overview
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Strategic Overview
    • 18.3.3. FUJIFILM Holdings Corporation
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Financial Overview
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Strategic Overview
    • 18.3.4. Grail
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Financial Overview
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Strategic Overview
    • 18.3.5. Laboratory Corporation of America Holdings
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Financial Overview
      • 18.3.5.4. SWOT Analysis
    • 18.3.6. Thermo Fisher Scientific
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Financial Overview
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Myriad Genetics, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Financial Overview
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Canon Medical Systems Corporation
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Financial Overview
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Strategic Overview
    • 18.3.9. QIAGEN N.V.
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Financial Overview
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Illumina, Inc.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Financial Overview
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Strategic Overview
    • 18.3.11. Ambry Genetics
      • 18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. Financial Overview
      • 18.3.11.4. SWOT Analysis
      • 18.3.11.5. Strategic Overview
    • 18.3.12. Invitae Corp.
      • 18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. Financial Overview
      • 18.3.12.4. SWOT Analysis
      • 18.3.12.5. Strategic Overview
    • 18.3.13. Centogene N.V.
      • 18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.13.2. Product Portfolio
      • 18.3.13.3. Financial Overview
      • 18.3.13.4. SWOT Analysis
      • 18.3.13.5. Strategic Overview